Akari Therapeutics Shares Jump As KRAS Cancer News Returns
Akari Therapeutics looked set to surge at the open Friday. The biotech said its main cancer drug posted positive preclinical data in KRAS-mutated pancreatic cancer and announced a $5.5 million private placement. Akari closed up nearly 50% at $5.14 on Thursday. Shares were quoted at $10.15 as of 8:39 a.m. EDT in premarket, StockAnalysis reported. Akari remains a preclinical firm without drug revenue, so this latest data is key for bulls watching AKTX-101. The new financing hands Akari added cash to try to move the program into human trials.